Zoetis Inc. (NYSE:ZTS) Shares Purchased by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 750.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 281,715 shares of the company’s stock after buying an additional 248,595 shares during the period. BI Asset Management Fondsmaeglerselskab A S owned 0.06% of Zoetis worth $45,900,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. boosted its holdings in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Murphy & Mullick Capital Management Corp purchased a new stake in shares of Zoetis during the 4th quarter valued at $44,000. Asset Planning Inc acquired a new stake in shares of Zoetis during the 4th quarter worth $58,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Zoetis in the 4th quarter worth $59,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock valued at $312,254 over the last three months. 0.16% of the stock is owned by insiders.

Zoetis Stock Performance

Zoetis stock opened at $148.64 on Friday. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a market capitalization of $66.32 billion, a price-to-earnings ratio of 27.17, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The firm’s fifty day moving average price is $160.04 and its 200 day moving average price is $169.96.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. On average, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.35%. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research reports. Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Stifel Nicolaus cut their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Finally, Piper Sandler increased their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $214.40.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.